ARTICLE | Clinical News
CV-301: Ph I/II started
January 5, 2017 9:59 PM UTC
Bavarian Nordic began an open-label, U.S. Phase I/II trial of CV-301 in about 120 patients who have failed prior therapy. The dose-escalation Phase I portion will evaluate CV-301 alone in 40 patients ...
BCIQ Company Profiles